Implantica Receives FDA Approval for RefluxStop, Opening the U.S. Market for GERD Treatment
核心洞察
The U.S. FDA granted Premarket Approval (PMA) for RefluxStop (搜索), Implantica's implant-based treatment for gastroesophageal reflux disease (搜索) (GERD), enabling U.S. commercial launch.
RefluxStop (搜索) addresses the root cause of acid reflux by restoring the natural anatomy of the gastroesophageal junction without encircling or applying pressure on the food passageway.
The approval follows FDA review of long-term clinical evidence, including published five-year safety and effectiveness outcomes, with close to 1,800 patients already treated in Europe.
Implantica AG (搜索), a medtech company headquartered in Vaduz, Liechtenstein, announced that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for RefluxStop (搜索), the company's implant-based treatment for gastroesophageal reflux disease (搜索) (GERD). The approval, announced on August 21, 2026, allows Implantica to begin commercial launch activities in the United States, which the company describes as the world's largest medical device market.
The FDA approval follows the agency's full review of the RefluxStop (搜索) PMA application, including long-term clinical evidence supporting the five-year safety and effectiveness of the therapy. RefluxStop is designed to address the underlying cause of acid reflux by restoring and maintaining the natural anatomy of the gastroesophageal junction, without encircling or applying pressure on the food passageway.
Dr. Peter Forsell, CEO and founder of Implantica, characterized the approval as "a defining landmark for Implantica and the culmination of many years of clinical development, scientific work, and rigorous regulatory review." He emphasized the scale of the opportunity, noting that "we can now bring RefluxStop (搜索) to the United States, where an estimated 78 million people suffer from acid reflux."
A Differentiated Mechanism of Action
RefluxStop (搜索) differs from conventional anti-reflux surgical procedures, which typically rely on encircling the esophagus and are often associated with side effects such as swallowing difficulties, inability to belch or vomit, and gas bloating. Instead, RefluxStop aims to restore and maintain the lower esophageal sphincter (搜索) in its natural anatomical position without encircling or applying pressure on the food passageway.
According to the company, commercial performance from a multitude of centers supports the clinical study data collected and shows that the RefluxStop (搜索) device can successfully treat GERD without wrapping or constricting the esophageal sphincter, thereby avoiding the side effects commonly seen with other current treatment approaches. Long-term five-year clinical outcomes on RefluxStop have been published in peer-reviewed scientific journals and support that a significant portion of the patient population will achieve clinically meaningful results, with minimal risks, when used in accordance with the indications for use.
Indications for Use
RefluxStop (搜索) is an implantable sterile medical device intended to treat acid and non-acid reflux in patients diagnosed with GERD. The device ensures maintenance of a normal physiological situation for the gastroesophageal junction (GEJ) in a defined intra-abdominal position, allowing natural physiological function of the lower esophageal sphincter (搜索) (LES), thereby reducing or eliminating acid and non-acid reflux. The RefluxStop Deployment Tool is indicated for patients diagnosed with GERD, defined by abnormal impedance pH and/or pH testing, and indicated for RefluxStop implantation.
Commercial Foundation and U.S. Launch Strategy
Implantica enters the U.S. market with a substantially more mature clinical and commercial foundation than is typical for a newly approved medical device. RefluxStop (搜索) already has several years of commercial experience in Europe, with close to 1,800 patients treated and more than 60 Centers of Excellence across nine European countries, alongside published five-year clinical outcomes.
Dr. Forsell outlined the company's launch approach: "FDA approval changes our focus from preparation to execution. As the world's largest medtech market, the United States represents a substantial commercial growth opportunity for Implantica, and we are very excited to begin the U.S. launch of RefluxStop (搜索)." He added that the initial rollout will be targeted, focusing on selected leading U.S. centers and reflux surgeons, with commercial adoption expected to build gradually, reflecting the physician training and site activation required to establish RefluxStop at each center.
About Implantica
Implantica is a medtech company focused on bringing advanced implantable technologies into the body designed to improve patient outcomes and quality of life. The company's lead product, RefluxStop (搜索), is an FDA-approved and CE-marked implant for the treatment of GERD with the potential to transform the standard of care in anti-reflux surgery, supported by strong long-term clinical outcomes. In addition to RefluxStop, Implantica has developed a broad, patent-protected product pipeline incorporating two platform technologies: an eHealth platform designed to enable communication with and remote monitoring and control of implants inside the body, and a wireless energizing platform designed to wirelessly power implantable devices through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm (ticker: IMP A SDB).